ImmunityBio

Oncology

ESMO25: Harnessing the innate and the adaptive immune respon...

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Oncology

ASCO 2025 interview with Dr Sandeep Reddy

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bl...

News

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product.

News

FDA rejects ImmunityBio’s bladder cancer drug

Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.

News

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBi...

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio.

ESMO25: Harnessing the innate and the adaptive immune respon...

ImmunityBio’s ANKTIVA & FDA Expanded Access: Transforming bl...

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

FDA rejects ImmunityBio’s bladder cancer drug

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBi...

Consolidating data strategy for global success: Insights fro...

How to meet your physicians where they are online

ImmunityBio

Editor's Picks